Published in Proc Natl Acad Sci U S A on September 02, 1997
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature (2008) 12.21
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A (1999) 7.60
SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell (2008) 4.54
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci (2009) 4.16
Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol (2003) 3.40
The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci (2013) 3.16
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest (2007) 3.11
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol (2003) 2.94
Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One (2007) 2.70
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A (2003) 2.65
SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J (2001) 2.51
Residual Cajal bodies in coilin knockout mice fail to recruit Sm snRNPs and SMN, the spinal muscular atrophy gene product. J Cell Biol (2001) 2.49
A functional interaction between the survival motor neuron complex and RNA polymerase II. J Cell Biol (2001) 2.44
Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet (2008) 2.35
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 2.29
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet (1999) 2.21
SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc Natl Acad Sci U S A (1999) 2.18
A day in the life of the spliceosome. Nat Rev Mol Cell Biol (2014) 2.18
The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. J Cell Biol (1999) 2.17
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet (2011) 2.13
Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis (2007) 2.10
Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes Dev (2001) 2.03
Gene function in early mouse embryonic stem cell differentiation. BMC Genomics (2007) 1.96
Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res (2006) 1.84
Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet (2008) 1.79
Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet (2009) 1.76
A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol (2003) 1.75
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol (2001) 1.64
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest (2011) 1.62
Proliferation failure and gamma radiation sensitivity of Fen1 null mutant mice at the blastocyst stage. Mol Cell Biol (2003) 1.59
Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy. J Cell Biol (2007) 1.57
Coiled bodies and gems: Janus or gemini? Am J Hum Genet (1998) 1.51
Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci (2010) 1.49
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet (2009) 1.46
Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol (2004) 1.45
Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med (2012) 1.44
Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet (2011) 1.44
Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci (2012) 1.42
Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One (2012) 1.40
Reduced viability, fertility and fecundity in mice lacking the cajal body marker protein, coilin. PLoS One (2009) 1.35
Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet (2008) 1.32
A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum Mol Genet (2009) 1.31
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
Structure of a key intermediate of the SMN complex reveals Gemin2's crucial function in snRNP assembly. Cell (2011) 1.29
Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res (2012) 1.26
High-resolution genetic and physical map of the Lgn1 interval in C57BL/6J implicates Naip2 or Naip5 in Legionella pneumophila pathogenesis. Genome Res (2000) 1.26
Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol (2011) 1.26
Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am J Pathol (2004) 1.24
Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects. Hum Mol Genet (2009) 1.24
Gene targeting of Gemin2 in mice reveals a correlation between defects in the biogenesis of U snRNPs and motoneuron cell death. Proc Natl Acad Sci U S A (2002) 1.23
Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep (2010) 1.21
Host proteins interacting with the Moloney murine leukemia virus integrase: multiple transcriptional regulators and chromatin binding factors. Retrovirology (2008) 1.20
Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet (2009) 1.19
Fibrillarin is essential for early development and required for accumulation of an intron-encoded small nucleolar RNA in the mouse. Mol Cell Biol (2003) 1.17
Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ (2009) 1.17
Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol (2012) 1.17
Stem cell technology for the study and treatment of motor neuron diseases. Regen Med (2011) 1.16
The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech (2011) 1.15
Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A (2000) 1.14
The product of the survival of motor neuron (SMN) gene is a human telomerase-associated protein. Mol Biol Cell (2002) 1.14
Refined characterization of the expression and stability of the SMN gene products. Am J Pathol (2007) 1.14
Fliih, a gelsolin-related cytoskeletal regulator essential for early mammalian embryonic development. Mol Cell Biol (2002) 1.13
Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol (2014) 1.13
Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun (2009) 1.12
Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS One (2010) 1.11
ARS2 is a conserved eukaryotic gene essential for early mammalian development. Mol Cell Biol (2007) 1.10
Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol (2007) 1.10
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum Mol Genet (2008) 1.08
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One (2012) 1.08
Survival motor neuron affects plastin 3 protein levels leading to motor defects. J Neurosci (2012) 1.07
Inactivation of the SMN complex by oxidative stress. Mol Cell (2008) 1.06
Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest (2014) 1.06
Functional cooperation of Epstein-Barr virus nuclear antigen 2 and the survival motor neuron protein in transactivation of the viral LMP1 promoter. J Virol (2001) 1.05
Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med (2012) 1.05
Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene. J Biol Chem (2004) 1.03
A screen for regulators of survival of motor neuron protein levels. Nat Chem Biol (2011) 1.02
Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems. Am J Pathol (2002) 1.02
Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol (2013) 1.01
A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. J Neurosci Methods (2006) 1.00
ZPR1 is essential for survival and is required for localization of the survival motor neurons (SMN) protein to Cajal bodies. Mol Cell Biol (2005) 0.99
Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev (2010) 0.98
Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models. Hum Mol Genet (2012) 0.96
Splicing regulation of the survival motor neuron genes and implications for treatment of spinal muscular atrophy. Front Biosci (Landmark Ed) (2010) 0.96
Mouse models of SMA: tools for disease characterization and therapeutic development. Hum Genet (2012) 0.96
Modeling spinal muscular atrophy in Drosophila links Smn to FGF signaling. J Cell Biol (2011) 0.96
Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther (2013) 0.95
Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve (2014) 0.95
Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene. Mol Neurodegener (2011) 0.94
More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front Physiol (2013) 0.94
Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy. Skelet Muscle (2013) 0.94
Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest (2011) 0.94
Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93
Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. RNA Biol (2011) 0.93
Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues. Proc Natl Acad Sci U S A (1998) 0.92
Gemin3 is an essential gene required for larval motor function and pupation in Drosophila. Mol Biol Cell (2008) 0.92
DEAD-box protein-103 (DP103, Ddx20) is essential for early embryonic development and modulates ovarian morphology and function. Endocrinology (2008) 0.92
Reduced levels of survival motor neuron protein leads to aberrant motoneuron growth in a Xenopus model of muscular atrophy. Neurogenetics (2009) 0.91
Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41
A workbench for multiple alignment construction and analysis. Proteins (1991) 16.96
Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J (1986) 11.41
A novel nuclear structure containing the survival of motor neurons protein. EMBO J (1996) 4.72
Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature (1996) 4.55
Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature (1990) 3.77
Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature (1990) 3.48
Classification of spinal muscular atrophies. Lancet (1980) 3.40
Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators. Lancet (1990) 3.12
Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature (1990) 2.73
Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Hum Mol Genet (1995) 2.59
Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol (1995) 2.56
Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet (1995) 2.34
Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet (1995) 2.33
A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet (1995) 2.24
Disruption of the CNTF gene results in motor neuron degeneration. Nature (1993) 2.22
A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. Nat Genet (1995) 2.17
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06
Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype. Hum Mol Genet (1996) 1.83
Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy. Hum Mol Genet (1996) 1.61
Targeted replacement of the homeobox gene Hox-3.1 by the Escherichia coli lacZ in mouse chimeric embryos. Proc Natl Acad Sci U S A (1990) 1.42
Genes for SMA: multum in parvo. Cell (1995) 1.39
Cell redundancy in the zona-intact preimplantation mouse blastocyst: a light and electron microscope study of dead cells and their fate. J Embryol Exp Morphol (1974) 1.33
Application of LacZ gene fusions to preimplantation development. Methods Enzymol (1993) 1.09
Two large insert vectors, lambda PS and lambda KO, facilitate rapid mapping and targeted disruption of mammalian genes. Biotechniques (1994) 1.08
From enigmatic to problematic: the new molecular genetics of childhood spinal muscular atrophy. Neurology (1996) 1.05
SMA genes: deleted and duplicated. Nat Genet (1995) 0.92
Deletion analysis of SMN and NAIP genes in spinal muscular atrophy Italian families. Muscle Nerve (1996) 0.90
Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet (2000) 21.52
Variation in general practitioners' referral rates to consultants. J R Coll Gen Pract (1987) 12.16
INTERNAL STRUCTURE AND NUCLEI IN CELLS OF ESCHERICHIA COLI AS SHOWN BY IMPROVED ELECTRON MICROSCOPIC TECHNIQUES. J Bacteriol (1949) 7.86
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
Buffalo rat liver cells produce a diffusible activity which inhibits the differentiation of murine embryonal carcinoma and embryonic stem cells. Dev Biol (1987) 5.96
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood (1998) 3.06
HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med (1997) 3.03
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood (2001) 2.61
Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care (2001) 2.53
Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med (2000) 2.50
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
A clinical investigation of the portacaval shunt. V. Survival analysis of the therapeutic operation. Ann Surg (1971) 2.46
Establishment of germ-line-competent embryonic stem (ES) cells using differentiation inhibiting activity. Development (1990) 2.42
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol (1998) 2.37
Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci (1997) 2.33
Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci U S A (1998) 2.32
Functional analysis of 150 deletion mutants in Saccharomyces cerevisiae by a systematic approach. Mol Gen Genet (1999) 2.26
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Disruption of the CNTF gene results in motor neuron degeneration. Nature (1993) 2.22
The Use of Sulphocyanate of Soda in High Blood Pressure. Can Med Assoc J (1928) 2.20
The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology (1994) 2.19
Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol (1999) 2.15
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage. Cell (1990) 2.10
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
t(8;21) myelodysplasia, an early presentation of M2 AML. Br J Haematol (1995) 2.08
Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet (2001) 2.00
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol (2000) 1.96
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med (1993) 1.92
Rapid loss of Oct-4 and pluripotency in cultured rodent blastocysts and derivative cell lines. Biol Reprod (2003) 1.91
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Crystal structure of aspartate decarboxylase at 2.2 A resolution provides evidence for an ester in protein self-processing. Nat Struct Biol (1998) 1.89
Telomere directed fragmentation of mammalian chromosomes. Nucleic Acids Res (1993) 1.88
Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve (2001) 1.85
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology (2010) 1.80
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature (1990) 1.80
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler (2001) 1.76
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Essential function of LIF receptor in motor neurons. Nature (1995) 1.74
A clinical investigation of the portacaval shunt. II. Survival analysis of the prophylactic operation. Am J Surg (1968) 1.72
Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci (1999) 1.71
Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. Trends Genet (1995) 1.68
Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood (1995) 1.68
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood (1997) 1.65
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Linkage of proximal myotonic myopathy to chromosome 3q. Neurology (1999) 1.60
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet (1995) 1.60
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Multiple genes encoding the conserved CCAAT-box transcription factor complex are expressed in Arabidopsis. Plant Physiol (1998) 1.59
Rhizobium meliloti swims by unidirectional, intermittent rotation of right-handed flagellar helices. J Bacteriol (1987) 1.59
Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol (2002) 1.54
Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci (1990) 1.53
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Management of hemorrhage after percutaneous renal surgery. J Urol (1995) 1.53
Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med (2000) 1.52
Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci (1998) 1.51
Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet (2000) 1.50
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt (2002) 1.50
Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve (2000) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol (1994) 1.49
Ototoxicity induced by once-daily gentamicin. Lancet (1998) 1.48
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Inhibition of protohaem ferro-lyase by N-substituted porphyrins. Structural requirements for the inhibitory effect. Biochem J (1980) 1.46
ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neurons. Neuron (1989) 1.46
A Schwann cell mitogen accompanying regeneration of motor neurons. Nature (1997) 1.44
The detection by immunodiffusion of tumour associated antigenic components in extracts of human bronchongenic carcinoma. Br J Cancer (1975) 1.42
Nucleic acid concentrations in normal human plasma. Clin Chem (1972) 1.42
VZV spinal cord infarction identified by diffusion-weighted MRI (DWI). Neurology (2007) 1.41
Does oligodendrocyte survival depend on axons? Curr Biol (1993) 1.40
Binding of neurotrophin-3 to its neuronal receptors and interactions with nerve growth factor and brain-derived neurotrophic factor. EMBO J (1992) 1.36
Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation. Neuron (1996) 1.36
Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron (1996) 1.35
Structure of complex flagellar filaments in Rhizobium meliloti. J Bacteriol (1985) 1.34
Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature (1988) 1.34
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34
Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet (1995) 1.33
Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations. Genes Dev (1990) 1.32
A single precursor protein for ferrochelatase-I from Arabidopsis is imported in vitro into both chloroplasts and mitochondria. J Biol Chem (1997) 1.32
Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst (2001) 1.32
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res (2001) 1.32
Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology (2011) 1.32
Use of paraffin wax embedded bone marrow trephine biopsy specimens as a source of archival DNA. J Clin Pathol (1992) 1.31